Previous Article | Next Article ![]()
Journal of Virology, October 1999, p. 8630-8639, Vol. 73, No. 10
Departments of Microbiology and
Immunology1 and
Pediatrics,3 University of Rochester
Medical Center, Rochester, New York; Divisions of Microbiology
and Immunology2 and Research
Resources,4 Yerkes Regional Primate
Research Center,
Received 24 February 1999/Accepted 9 July 1999
The fatal disease induced by SIVsmmPBj4 clinically resembles
endotoxic shock, with the development of severe gastrointestinal disease. While the exact mechanism of disease induction has not been
fully elucidated, aspects of virus biology suggest that immune activation contributes to pathogenesis. These biological
characteristics include induction of peripheral blood mononuclear cell
(PBMC) proliferation, upregulation of activation markers and Fas ligand expression, and increased levels of apoptosis. To investigate the role
of immune activation and viral replication on disease induction,
animals infected with SIVsmmPBj14 were treated with one of two drugs:
FK-506, a potent immunosuppressive agent, or PMPA, a potent
antiretroviral agent. While PBMC proliferation was blocked in vitro
with FK-506, pig-tailed macaques treated preinoculation with FK-506
were not protected from acutely lethal disease. However, these animals
did show some evidence of modulation of immune activation, including
reduced levels of CD25 antigen and FasL expression, as well as lower
tissue viral loads. In contrast, macaques treated postinoculation with
PMPA were completely protected from the development of acutely lethal
disease. Treatment with PMPA beginning as late as 5 days postinfection
was able to prevent the PBj syndrome. Plasma and cellular viral loads
in PMPA-treated animals were significantly lower than those in
untreated controls. Although PMPA-treated animals showed acute
lymphopenia due to SIVsmmPBj14 infection, cell subset levels
subsequently recovered and returned to normal. Based upon subsequent
CD4+ cell counts, the results suggest that very early
treatment following retroviral infection can have a significant effect
on modifying the subsequent course of disease. These results also
suggest that viral replication is an important factor involved in
PBJ-induced disease. These studies reinforce the idea that the
SIVsmmPBj model system is useful for therapy and vaccine testing.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Postinoculation PMPA Treatment, but Not
Preinoculation Immunomodulatory Therapy, Protects against
Development of Acute Disease Induced by the Unique Simian
Immunodeficiency Virus SIVsmmPBj
*
Corresponding author. Mailing address: Yerkes Regional
Primate Research Center, 954 N. Gatewood Rd., Atlanta, GA 30322. Phone: (404) 727-7216. Fax: (404) 727-7845. E-mail:
fnovembr{at}rmy.emory.edu.
Journal of Virology, October 1999, p. 8630-8639, Vol. 73, No. 10
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»